What could a tree possibly reveal about the European Society for Medical Oncology (ESMO)? Quite a lot, says Prof Andres Cervantes, Professor of Medicine at the University of Valencia, Spain ...

Regeneron Pharmaceuticals’ investigational melanoma combination therapy shows continued response after two years in a Phase I ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

Susanne Bobadilla from VML Health, joined by a team of 15 medical, digital strategists and client engagement experts from across the company, looks at the top trends coming out of ESMO 2024 and what ...

Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient ...

Good morning and welcome to Agenus' third quarter 2024 conference call and webcast. All participants will be in a listen-only ...

(esmo), a leading global full-service systems integrator, developer, and supplier of innovative and advanced automation ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

Now, new data from the POD1UM-303 study reported at ESMO suggests the company could resurrect the SCAC indication and move Zynyz into the first-line setting to boot. Given in combination with ...

Shares of Sutro Biopharma (NASDAQ:STRO) fell by 17% in September after the company's ESMO (European Society for Medical Oncology) update. 3-year performance isn't looking much better at -81% ...

EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...